Mosbech H, Djurup R, Dreborg S, Kaergaard Poulsen L, Stahl Skov P, Steringer I
Medical Dept., State University Hospital, Copenhagen, Denmark.
Allergy. 1990 Feb;45(2):130-41. doi: 10.1111/j.1398-9995.1990.tb00471.x.
Forty-six adult asthmatics allergic to D. pteronyssinus (Dp) participated in a 2-year study. Thirty-one underwent hyposensitization (HS-group). Fifteen were treated with Dp-extract (Dp-group), and 16 with a similar extract modified by monomethoxypolyethylene glycol with reduced allergenicity (mPEG-Dp-group). Fifteen patients served as controls. Dp-specific antibodies and histamine release from blood basophils were determined and compared with Dp-sensitivity in lungs and skin. In addition, IgG and IgE against the major allergen Der p I were followed in a subgroup. Dp-specific IgG, IgG1, and IgG4 increased significantly in both HS-treated groups after 1 and 2 years (median: 2.5- to 11.6-fold). IgG4 was not induced if maintenance dose during the first year was less than 20,000 BU. Median skin sensitivity decreased 4.4- to 8.2-fold after 1 year and 7.4- to 21.4-fold after 2 years. Der p I specific IgG response was unrelated to the occurrence or change in IgE with the same specificity. The mPEG-Dp-extract tended to have less effect on skin sensitivity and immunological parameters, differences reaching statistical significance for skin sensitivity only. In the HS-group, the decrease in bronchial sensitivity was significantly correlated to a decrease in IgE (r = 0.36), IgG1/IgG4 (r = 0.49), Dp-specific histamine release (r = 0.58), and to an increase in Dp-specific IgG4 (r = -0.36) and IgG4/IgE (r = -0.48). In patients improving clinically, Dp-specific IgG4/IgE increased, and median Dp-specific IgE was reduced to 80% compared with an increase to 150-160% seen in the unchanged or deteriorated group (P less than 0.05). Findings indicate an improvement of effect, if the allergen dose is sufficient to reduce specific IgE and/or induce an IgG and especially IgG4 response.
46名对屋尘螨(Dp)过敏的成年哮喘患者参与了一项为期2年的研究。31名患者接受了脱敏治疗(HS组)。15名患者接受Dp提取物治疗(Dp组),16名患者接受经单甲氧基聚乙二醇修饰、变应原性降低的类似提取物治疗(mPEG-Dp组)。15名患者作为对照。测定了Dp特异性抗体和血液嗜碱性粒细胞释放的组胺,并与肺部和皮肤的Dp敏感性进行比较。此外,在一个亚组中跟踪了针对主要变应原Der p I的IgG和IgE。在两个接受HS治疗的组中,1年和2年后Dp特异性IgG、IgG1和IgG4均显著增加(中位数:增加2.5至11.6倍)。如果第一年的维持剂量小于20,000 BU,则不会诱导产生IgG4。1年后皮肤敏感性中位数降低4.4至8.2倍,2年后降低7.4至21.4倍。Der p I特异性IgG反应与具有相同特异性的IgE的发生或变化无关。mPEG-Dp提取物对皮肤敏感性和免疫参数的影响往往较小,仅皮肤敏感性的差异达到统计学意义。在HS组中,支气管敏感性的降低与IgE的降低(r = 0.36)、IgG1/IgG4的降低(r = 0.49)、Dp特异性组胺释放的降低(r = 0.58)以及Dp特异性IgG4的增加(r = -0.36)和IgG4/IgE的增加(r = -0.48)显著相关。在临床改善的患者中,Dp特异性IgG4/IgE增加,Dp特异性IgE中位数降至80%,而在病情未改变或恶化的组中则增加至150 - 160%(P < 0.05)。研究结果表明,如果变应原剂量足以降低特异性IgE和/或诱导IgG尤其是IgG4反应,则效果会有所改善。